Crinetics Pharmaceuticals, Inc.
For the period ended Dec 31, 2025. Filed Feb 26, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 26, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Signatures
Checking your notes…
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized.
| Crinetics Pharmaceuticals, Inc. | ||
| Date: February 26, 2026 | By: | /s/ R. Scott Struthers, Ph.D. |
|---|---|---|
| R. Scott Struthers, Ph.D. | ||
| President and Chief Executive Officer | ||
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this Report has been signed below by the following persons on behalf of the Registrant in the capacities and on the dates indicated.
| Name | Title | Date |
|---|---|---|
| /s/ R. Scott Struthers, Ph.D. | President, Chief Executive Officer and Director | February 26, 2026 |
| R. Scott Struthers, Ph.D. | (principal executive officer) | |
| /s/ Tobin Schilke | Chief Financial Officer | February 26, 2026 |
| Tobin Schilke | (principal financial and accounting officer) | |
| /s/ Wendell Wierenga, Ph.D. | Chairman of the Board of Directors | February 26, 2026 |
| Wendell Wierenga, Ph.D. | ||
| /s/ Camille Bedrosian, M.D. | Director | February 26, 2026 |
| Camille Bedrosian, M.D. | ||
| /s/ Caren Deardorf | Director | February 26, 2026 |
| Caren Deardorf | ||
| /s/ Matthew K. Fust | Director | February 26, 2026 |
| Matthew K. Fust | ||
| /s/ Weston Nichols, Ph.D. | Director | February 26, 2026 |
| Weston Nichols, Ph.D. | ||
| /s/ Stephanie Okey | Director | February 26, 2026 |
| Stephanie Okey | ||
| /s/ Rogério Vivaldi Coelho, M.D. | Director | February 26, 2026 |
| Rogério Vivaldi Coelho, M.D. | ||
i
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.